175 related articles for article (PubMed ID: 30649413)
21. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
22. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
[TBL] [Abstract][Full Text] [Related]
23. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.
Michallet M; Sobh M; Morisset S; Kraghel S; Nicolini FE; Thomas X; Bienvenu AL; Picot S; Nicolle MC; Vanhems P
Med Mycol; 2011 Oct; 49(7):681-7. PubMed ID: 21314250
[TBL] [Abstract][Full Text] [Related]
25. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
Miranti E; Ho DY; Enriquez K; Subramanian AK; Medeiros BC; Epstein DJ
Leuk Lymphoma; 2022 Sep; 63(9):2206-2212. PubMed ID: 35410569
[TBL] [Abstract][Full Text] [Related]
27. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
28. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis.
Soldi LR; Coelho YNB; Paranhos LR; Silva MJB
Clin Exp Med; 2023 Nov; 23(7):3231-3249. PubMed ID: 37058186
[TBL] [Abstract][Full Text] [Related]
29. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
30. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.
Pagano L; Caira M; Nosari A; Van Lint MT; Candoni A; Offidani M; Aloisi T; Irrera G; Bonini A; Picardi M; Caramatti C; Invernizzi R; Mattei D; Melillo L; de Waure C; Reddiconto G; Fianchi L; Valentini CG; Girmenia C; Leone G; Aversa F
Clin Infect Dis; 2007 Nov; 45(9):1161-70. PubMed ID: 17918077
[TBL] [Abstract][Full Text] [Related]
31. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.
Tober R; Schnetzke U; Fleischmann M; Yomade O; Schrenk K; Hammersen J; Glaser A; Thiede C; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1569-1583. PubMed ID: 35583829
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Tey A; Shaw B; Cardamone L; Shepherd S; Paul E; Rogers B; Shortt J
Eur J Haematol; 2021 Aug; 107(2):181-189. PubMed ID: 33829584
[TBL] [Abstract][Full Text] [Related]
33. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
34. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
[TBL] [Abstract][Full Text] [Related]
35. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis.
Signorelli J; Lei M; Lam J; Jalbut M; Amrein PC; Fathi AT; Hobbs G; Hock H; McAfee SL; Letourneau AR; Narayan R; Brunner A
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e883-e889. PubMed ID: 32917574
[TBL] [Abstract][Full Text] [Related]
36. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
37. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).
Caira M; Candoni A; Verga L; Busca A; Delia M; Nosari A; Caramatti C; Castagnola C; Cattaneo C; Fanci R; Chierichini A; Melillo L; Mitra ME; Picardi M; Potenza L; Salutari P; Vianelli N; Facchini L; Cesarini M; De Paolis MR; Di Blasi R; Farina F; Venditti A; Ferrari A; Garzia M; Gasbarrino C; Invernizzi R; Lessi F; Manna A; Martino B; Nadali G; Offidani M; Paris L; Pavone V; Rossi G; Spadea A; Specchia G; Trecarichi EM; Vacca A; Cesaro S; Perriello V; Aversa F; Tumbarello M; Pagano L;
Haematologica; 2015 Feb; 100(2):284-92. PubMed ID: 25638805
[TBL] [Abstract][Full Text] [Related]
38. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome.
van de Peppel RJ; Dekkers OM; von dem Borne PA; de Boer MG
Med Mycol; 2014 Oct; 52(7):699-705. PubMed ID: 25049037
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
40. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years.
Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY
J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
